Update on FOCUS Trial of CA4P in Ovarian Cancer Expected in Late Summer
News
Second preliminary results from the FOCUS Phase 2/3 trial assessing the safety and effectiveness of Mateon Therapeutics’ drug candidate CA4P in combination with standard-of-care therapies for platinum-resistant ovarian cancer are expected ... Read more